Study shows how functional biomaterials rely on interfacial protein layer to transmit signals to living cells
An interdisciplinary research team at Lehigh University has unraveled how functional biomaterials rely upon an interfacial protein layer to transmit signals to living cells concerning their adhesion, proliferation and overall development.
According to an article published today in
Scientific Reports, the nanoscale features and properties of an underlying substrate do not impact the biological response of cells directly. However, these properties indirectly influence cell behavior through their control over adsorbed proteins.
In the article, Nanostructure of bioactive glass affects bone cell attachment via protein restructuring upon adsorption, the Lehigh team demonstrates that living cells respond to interfacial layer characteristics that arise as a consequence of micro- and nano-scale structures engineered into a substrate material.
Sweden’s probiotics firm Probi continues its collaborative mood by striking an agreement with an Australian-based university to pursue further insights into how probiotics promote bone health.
The agreement with Melbourne-based La Trobe University reiterates Probi’s efforts into what influences bone strength, particularly in later years and where the gut microbiome fits into bone metabolism, microarchitecture and density.
“Recent scientific evidence has consistently highlighted the important role of the gut microbiome on bone health,” explains research group leader Dr George Moschonis at La Trobe University,
“Considering these breakthrough discoveries, we are excited to contribute our strengths into further extending the current knowledge and produce additional high-quality research evidence that will shed more light on the effectiveness of probiotics in the reduction of bone loss,” adds Dr Moschonis, an Associate Professor at the univ
Bone marrow cell injections may lead to reduction in brain injury after stroke
Results of a clinical trial released in
STEM CELLS Translational Medicine provide evidence that treating patients with an injection of bone marrow cells may lead to a reduction in brain injury after a stroke.
The study was conducted by Muhammad E. Haque, Ph.D., Sean I. Savitz, M.D., and colleagues from the Institute for Stroke and Cerebrovascular Disease at The University of Texas Health Science Center in Houston.
Nearly 90 percent of patients who suffer an ischemic stroke - the most common type of stroke - exhibit weakness or paralysis to one side of the body. Injuries to the corticospinal tract (CST), which is the main white matter connection in the brain responsible for carrying movement-related information to the spinal cord, is the primary cause of this motor function impairment. In stroke animal models, we ve seen how bone marrow mononuclear cells (BM-MNC) attenuate secondary degeneration and en
An interesting new preprint research paper posted to the medRxiv server reports there is little evidence to suggest the rapid transmission of the virus among school children while attending school.
Whole genome sequencing may guide blood cancer treatment
For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes.
Some of these tests rely on technology that was invented more than 60 years ago and has been used clinically for the past three decades.
Now, a new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing. In addition, results can be returned to patients in just a few days, making whole genome sequencing a potentially viable approach for determining the best treatment regimen for a particular patien